| Name | Title | Contact Details |
|---|
Avaxia is a leader in the growing field of gut-targeted therapeutics — orally administered, minimally absorbed drugs that are designed to act locally in the gastrointestinal tract. Avaxia’s lead clinical candidate, AVX-470, is an oral anti-TNF antibody for inflammatory bowel disease. This transformative product offers potentially improved safety and efficacy over existing anti-TNF therapies by focusing immune suppression only where needed in the diseased gut. Avaxia plans to use its gut-targeted antibody platform to develop therapeutics to address many other serious diseases such as type 2 diabetes, celiac disease, GI acute radiation syndrome and oral mucositis.
ISOAID is a Port Richey, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
American Physician Partners was founded in 2015 to provide a better alternative to hospitals for their clinical outsourcing needs. Since its inception, the company has grown to more than 160 care sites and has become a recognized leader in the provision of exceptional emergency medicine and hospital medicine management services to hospitals and healthcare systems nationwide. APP has earned its 100 percent client retention rate by remaining true to its purpose of exceeding the expectations of its patients, providers and hospital partners.
Orthodontic Associates is a Watertown, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Air Force Insurance Fund is a San Antonio, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.